Whales with a lot of money to spend have taken a noticeably bearish stance on Novo Nordisk.
Looking at options history for Novo Nordisk NVO we detected 25 trades.
If we consider the specifics of each trade, it is accurate to state that 40% of the investors opened trades with bullish expectations and 48% with bearish.
From the overall spotted trades, 11 are puts, for a total amount of $1,872,600 and 14, calls, for a total amount of $3,590,645.
Projected Price Targets
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $65.0 to $145.0 for Novo Nordisk during the past quarter.
Volume & Open Interest Trends
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Novo Nordisk's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Novo Nordisk's substantial trades, within a strike price spectrum from $65.0 to $145.0 over the preceding 30 days.
Novo Nordisk Option Activity Analysis: Last 30 Days
Largest Options Trades Observed:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NVO | CALL | TRADE | BULLISH | 12/20/24 | $7.8 | $7.6 | $7.8 | $102.00 | $1.3M | 270 | 1.7K |
| NVO | PUT | TRADE | BEARISH | 01/17/25 | $5.2 | $4.9 | $5.2 | $100.00 | $780.0K | 4.6K | 2.0K |
| NVO | CALL | SWEEP | BULLISH | 01/17/25 | $3.85 | $3.65 | $3.84 | $115.00 | $686.9K | 2.9K | 1.9K |
| NVO | CALL | TRADE | BEARISH | 06/20/25 | $13.45 | $13.1 | $13.15 | $105.00 | $636.4K | 1.1K | 984 |
| NVO | PUT | SWEEP | BEARISH | 01/17/25 | $5.25 | $5.15 | $5.15 | $100.00 | $257.5K | 4.6K | 500 |
About Novo Nordisk
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Where Is Novo Nordisk Standing Right Now?
- With a volume of 4,857,497, the price of NVO is up 2.5% at $105.2.
- RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.
- Next earnings are expected to be released in 68 days.
What Analysts Are Saying About Novo Nordisk
1 market experts have recently issued ratings for this stock, with a consensus target price of $160.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access. * In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $160.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Novo Nordisk, Benzinga Pro gives you real-time options trades alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
